Kimberly A Nellenbach1, Seema Nandi, Alexander Kyu, Supriya Sivadanam, Nina A Guzzetta, Ashley C Brown. 1. From the Joint Department of Biomedical Engineering, North Carolina State University and The University of North Carolina at Chapel Hill, Raleigh, North Carolina (K.A.N., S.N., A.K., S.S., A.C.B.) the Comparative Medicine Institute, North Carolina State University, Raleigh, North Carolina (K.A.N., A.C.B.) the Department of Anesthesiology, Emory University School of Medicine and Children's Healthcare of Atlanta, Atlanta, Georgia (N.A.G.).
Abstract
BACKGROUND: Recent studies suggest that adult-specific treatment options for fibrinogen replacement during bleeding may be less effective in neonates. This is likely due to structural and functional differences found in the fibrin network between adults and neonates. In this investigation, the authors performed a comparative laboratory-based study between immature and adult human and porcine plasma samples in order to determine if piglets are an appropriate animal model of neonatal coagulopathy. METHODS: Adult and neonatal human and porcine plasma samples were collected from the Children's Hospital of Atlanta and North Carolina State University College of Veterinary Medicine, respectively. Clots were formed for analysis and fibrinogen concentration was quantified. Structure was examined through confocal microscopy and cryogenic scanning electron microscopy. Function was assessed through atomic force microscopy nanoindentation and clotting and fibrinolysis assays. Lastly, novel hemostatic therapies were applied to neonatal porcine samples to simulate treatment. RESULTS: All sample groups had similar plasma fibrinogen concentrations. Neonatal porcine and human plasma clots were less branched with lower fiber densities than the dense and highly branched networks seen in adult human and porcine clots. Neonatal porcine and human clots had faster degradation rates and lower clot stiffness values than adult clots (stiffness [mmHg] mean ± SD: neonatal human, 12.15 ± 1.35 mmHg vs. adult human, 32.25 ± 7.13 mmHg; P = 0.016; neonatal pig, 10.5 ± 8.25 mmHg vs. adult pigs, 32.55 ± 7.20 mmHg; P = 0.015). The addition of hemostatic therapies to neonatal porcine samples enhanced clot formation. CONCLUSIONS: The authors identified similar age-related patterns in structure, mechanical, and degradation properties between adults and neonates in porcine and human samples. These findings suggest that piglets are an appropriate preclinical model of neonatal coagulopathy. The authors also show the feasibility of in vitro model application through analysis of novel hemostatic therapies as applied to dilute neonatal porcine plasma.
BACKGROUND: Recent studies suggest that adult-specific treatment options for fibrinogen replacement during bleeding may be less effective in neonates. This is likely due to structural and functional differences found in the fibrin network between adults and neonates. In this investigation, the authors performed a comparative laboratory-based study between immature and adult human and porcine plasma samples in order to determine if piglets are an appropriate animal model of neonatal coagulopathy. METHODS: Adult and neonatal human and porcine plasma samples were collected from the Children's Hospital of Atlanta and North Carolina State University College of Veterinary Medicine, respectively. Clots were formed for analysis and fibrinogen concentration was quantified. Structure was examined through confocal microscopy and cryogenic scanning electron microscopy. Function was assessed through atomic force microscopy nanoindentation and clotting and fibrinolysis assays. Lastly, novel hemostatic therapies were applied to neonatal porcine samples to simulate treatment. RESULTS: All sample groups had similar plasma fibrinogen concentrations. Neonatal porcine and human plasma clots were less branched with lower fiber densities than the dense and highly branched networks seen in adult human and porcine clots. Neonatal porcine and human clots had faster degradation rates and lower clot stiffness values than adult clots (stiffness [mmHg] mean ± SD: neonatal human, 12.15 ± 1.35 mmHg vs. adult human, 32.25 ± 7.13 mmHg; P = 0.016; neonatal pig, 10.5 ± 8.25 mmHg vs. adult pigs, 32.55 ± 7.20 mmHg; P = 0.015). The addition of hemostatic therapies to neonatal porcine samples enhanced clot formation. CONCLUSIONS: The authors identified similar age-related patterns in structure, mechanical, and degradation properties between adults and neonates in porcine and human samples. These findings suggest that piglets are an appropriate preclinical model of neonatal coagulopathy. The authors also show the feasibility of in vitro model application through analysis of novel hemostatic therapies as applied to dilute neonatal porcine plasma.
Authors: Lucas H Timmins; Qiaofeng Wu; Alvin T Yeh; James E Moore; Stephen E Greenwald Journal: Am J Physiol Heart Circ Physiol Date: 2010-02-19 Impact factor: 4.733
Authors: Vera Ignjatovic; Cera Lai; Robyn Summerhayes; Ulrike Mathesius; Sherif Tawfilis; Matthew A Perugini; Paul Monagle Journal: PLoS One Date: 2011-02-18 Impact factor: 3.240
Authors: Ashley C Brown; Sarah E Stabenfeldt; Byungwook Ahn; Riley T Hannan; Kabir S Dhada; Emily S Herman; Victoria Stefanelli; Nina Guzzetta; Alexander Alexeev; Wilbur A Lam; L Andrew Lyon; Thomas H Barker Journal: Nat Mater Date: 2014-09-07 Impact factor: 43.841
Authors: Meredith A Achey; Uttara P Nag; Victoria L Robinson; Christopher R Reed; Gowthami M Arepally; Jerrold H Levy; Elisabeth T Tracy Journal: Clin Appl Thromb Hemost Date: 2020 Jan-Dec Impact factor: 2.389
Authors: Christopher R Reed; Desiree Bonadonna; James C Otto; Charles Griffin McDaniel; Charlene Vongai Chabata; Maragatha Kuchibhatla; James Frederiksen; Juliana M Layzer; Gowthami M Arepally; Bruce A Sullenger; Elisabeth T Tracy Journal: Mol Ther Nucleic Acids Date: 2021-12-11 Impact factor: 8.886